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Background: Indacaterol is a novel, inhaled once-daily ultra-long-acting beta-2 agonist under
development as a fixed-dose combination with an inhaled corticosteroid (ICS) for asthma treat-
ment. This study evaluated the 24-h bronchodilator efficacy of indacaterol in Japanese
patients with asthma.
Methods: Randomised, placebo-controlled, 5-period crossover study. Patients with persistent
asthma (18e75 years, FEV1 50e85% predicted, 12% and 200 mL FEV1 reversibility) receiving
ICS were randomised to double-blind single dose indacaterol 150, 300, or 600 mg or placebo,
with open-label salmeterol 50 mg twice-daily for one day in the 5th period. Primary endpoint
was FEV1AUC22e24h.
Results: Of 41 randomised patients (48.8% male; mean age: 47.8 years), 39 completed. All in-
dacaterol doses showed significantly higher FEV1AUC22e24h than placebo (P< 0.001), with
treatmenteplacebo differences of 180, 220, and 260 mL for indacaterol 150, 300, and
600 mg, respectively (salmeteroleplacebo difference 170 mL; P < 0.001). For individual
time-point FEV1, all indacaterol doses were superior to placebo from 5 min to 24 h post-dose3797 5254; fax: þ81 3 3797 5426.
rtis.com (M. Hosoe).
0 Elsevier Ltd. All rights reserved.
1630 N. Sugihara et al.(P < 0.001). Compared with salmeterol, all indacaterol doses were superior from 5 to 30 min
(P < 0.05); in addition indacaterol 300 mg and 600 mg were superior at a number of subsequent
time points. Changes in safety parameters with indacaterol were similar to placebo. All inda-
caterol doses were well tolerated.
Conclusion: Single dose indacaterol provided sustained 24-h bronchodilation with a faster
onset of action than salmeterol and a good overall safety and tolerability profile in Japanese
patients with asthma. These results are consistent with data from Caucasian populations.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Worldwide, asthma affects people of all ages causing
substantial debilitating symptoms and leading to a reduced
quality of life.1,2 Evidence from most studies, including
longitudinal surveys, suggests that the prevalence of
asthma has increased over the past decades in many parts
of the world, including Japan.3e7 Persistent asthma is most
effectively controlled with inhaled corticosteroids (ICSs)
administered daily on a long-term basis.8 For patients with
asthma not adequately controlled with a low-dose ICS
alone, current treatment guidelines recommend the addi-
tion of a long-acting beta-2 agonist (LABA) to the existing
ICS therapy.7e10
The goal of asthma management is to achieve and main-
tain control of symptoms e a major obstacle to which has
been low patient adherence to medication plans.11 A key
factor contributing to poor adherence is a complicated or
multiple treatment regimen, with simplified dosing regimens
known to improve compliance.11,12 Currently available
inhaled LABAs (e.g., salmeterol and formoterol) have an
approximately 12-h duration of action, necessitating twice-
daily (bid) dosing to provide optimal clinical efficacy.13,14
Thus the availability of a once-daily beta-2 agonist with
a24-hdurationof actioncombinedwitha once-daily ICS could
improve clinical outcomes in asthma by providing increased
patient convenience and sustained bronchodilation.
Indacaterol is a novel, once-daily, inhaled, ultra-LABA
under development as a fixed-dose combination with ICS for
the treatment of asthma. In preclinical studies, indacaterol
demonstrated a sustained bronchodilator and bronchopro-
tective effect, with a fast onset of action (comparable to
salbutamol and formoterol) and greater cardiovascular
safety margin than formoterol or salmeterol.15,16 Further-
more, in earlier clinical studies involving mostly the
Caucasian population, indacaterol showed effective 24-h
bronchodilation, with a fast onset of action and a good
overall safety and tolerability profile.17e21 The present
dose-ranging study was the first to investigate the 24-h
bronchodilatory efficacy and safety of single doses of
indacaterol 150, 300, and 600 mg delivered via a single-dose
dry-powder inhaler (SDDPI) in Japanese patients with
asthma. Given its similarity to a study conducted in
a Caucasian population it helps to evaluate the ethnic
sensitivity of the efficacy and safety of indacaterol.21
Methods
This was a Phase II, multicentre, randomised, double-blind,
placebo-controlled, crossover, dose-ranging study conductedbetween November 2006 and November 2007 at 11 speci-
alised allergy and respiratory care units in Japan
(ClinicalTrials.gov registration no.: NCT00403754).22 The
study was performed in accordance with the Declaration of
Helsinki and the International Conference on Harmonisation
Good Clinical Practice guidelines. The study was approved by
the institutional review board of each participating study
centre, and all patients provided written informed consent
before participating in the study.
Study population
The study recruited Japanese patients (aged 18e75 years)
with a clinical diagnosis of asthma according to the 2006
Japanese asthma prevention and management guideline7
(FEV1 between 50% and 85% of the predicted normal value
at screening, with 12% and 200 mL reversibility in FEV1
within 30 min after inhalation of salbutamol 200 mg). In
addition, patients must have received daily ICS treat-
mentddefined as fluticasone propionate 200e800 mg (or
equivalent)din a stable regimen for at least 4 weeks before
the screening visit (Visit 1).
Patients were excluded if they underwent hospitaliza-
tion or emergency room treatment for an acute exacerba-
tion of asthma in the 6 months before Visit 1, had
respiratory disease other than asthma, had respiratory
tract infection within 4 weeks before Visit 1, used tobacco
products within 6 months before Visit 1, or had a smoking
history of more than 10 pack-years. The other exclusion
criteria included seasonal allergies that might cause dete-
rioration of asthma; allergy to beta-2 agonists, sympatho-
mimetics, and inhaled medications; ischemic heart disease;
arrhythmia; uncontrolled hypertension; type 1 diabetes;
cancer; and a prolonged QT interval.
Study design and treatments
The study comprised a 14-day screening period, four
double-blind treatment periods (Visits 2e9), and an open-
label treatment period (Visits 10 and 11) (Fig. 1). The visits
on Day 1 and Day 2 of each treatment period were on
consecutive days. Following screening, all eligible patients
were randomised equally (at Visit 2), using a validated
automated system, to one of four treatment sequences to
receive a single dose of indacaterol 150, 300, and 600 mg or
placebo via an SDDPI. Patients who completed the double-
blind treatment period entered a single-day, open-label
treatment period with salmeterol 50 mg bid delivered via
the manufacturer’s proprietary multidose dry-powder
inhaler.
Figure 1 Study design. ( ) placebo, ( ) salmeterol 50 mg (bid), ( ) indacaterol 150 mg, ( ) indacaterol 300 mg and
( ) indacaterol 600 mg.
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drug was inhaled between 08:00 and 10:00 AM on Day 1
(Visits 2, 4, 6, and 8). During the open-label period (Visit
10), the first salmeterol dose was inhaled between 08:00
and 10:00 AM, and the second dose was inhaled after
spirometry at 12 h post-dose. Each treatment period was
separated by a 14e28 day washout period. Treatment
allocation was concealed from the patients, investigating
staff, and the clinical trial team by using study drugs that
were identical in packaging, labelling, appearance, and
administration schedule.
Concomitant medication
Other than ICS in a fixed-dose regimen that had been sta-
bilised for at least 4 weeks prior to Visit 1 with the ICS dose
remaining unchanged throughout the study, the following
asthma treatments were allowed between the treatment
periods (following the same regimen as the one before Visit
1): short-acting beta-2 agonists (6 h), LABAs (48 h),
xanthine derivatives (7 days), leukotriene antagonists
(72 h), and short-acting anticholinergics (8 h). These
treatments, however, had to be discontinued no later than
the specified time (mentioned within the parentheses
above) before Visits 1, 2, 4, 6, 8, and 10, and were not to be
recommenced until the completion of the last spirometry
evaluations at Visits 3, 5, 7, 9, and 11. Salbutamol was the
only rescue medication permitted throughout the study,
although visits had to be rescheduled if it was taken within
6 h prior to the first spirometry measurements during that
visit.
Assessments
Efficacy and safety were assessed for 24 h post-dose in each
treatment period. Efficacywas assessed by spirometry using
the same model of spirometer at all sites (MICROSPIRO HI-
201, Nihon Kohden Corporation, Tokyo, Japan). FEV1, FVC,
and FEF25e75% were determined pre-dose (15 min beforeinhalation of the studymedication), and at 5, 15, and 30 min
and 1, 2, 4, 8, 12, 22, 23, and 24 h post-dose. The primary
efficacy outcomewas the time-standardised area under the
curve (AUC) of FEV1 values measured between 22 and 24 h
post-dose (FEV1AUC22e24h). By using data from up to three
time points, this endpoint (which can be considered an
average of data from the three evaluations) has the
advantage of a smaller standard deviation compared with
a single time point, and provides more power for a given
number of patients. Further, since data forming this
endpoint are from the end of the dosing interval, this
endpoint should capture the lowest measured treat-
menteplacebo differences. Secondary efficacy outcomes
included percent change in FEV1 from baseline at each
individual time point post-dose; peak FEV1 (defined as the
maximum FEV1 value recorded between 5 min and 4 h post-
dose); standardised FEV1AUC0e24h; and individual time
point FEV1, FVC, and FEF25e75%.
Safety assessments involved recording of all adverse
events (AEs) and serious adverse events (SAEs) in all
treatment periods. The occurrence of AEs was sought by
non-directive questioning of patients at each visit during
the study, and may also have been detected when vol-
unteered by patients during or between visits or through
physical examination, laboratory test, or other assess-
ments. In addition, during the double-blind treatment
periods, safety was assessed by monitoringdat regular
time points in each treatment perioddof haematology and
blood biochemistry (including serum potassium and blood
glucose); urinalysis; and regular assessments of vital signs
and ECGs. During the open-label treatment period, with the
exception of adverse events no other safety data was
collected.
Sample size calculation and statistical analyses
The three main treatment comparisons were indacaterol
150 mg versus placebo, indacaterol 300 mg versus placebo,
and indacaterol 600 mg versus placebo. The sample size
1632 N. Sugihara et al.calculation was based on the post-dose primary efficacy
variable, standardised FEV1AUC22e24h. A standard deviation
(SD) of 283 mL,23 reversibility threshold of 12%, two-sided
significance level of 10% (adjusted to 3.3% using a Bonfer-
roni correction for the three main treatment comparisons),
and power of 85% were chosen for the sample size calcu-
lation. Assuming a drop out rate of 15% and to ensure
balance across the treatment sequences, 40 patients were
to be randomised in order to have at least 32 patients
completing the study.
The primary efficacy analysis was performed on a modi-
fied intention-to-treat (mITT) population, which included
all randomised patients who received at least one dose of
the study drug. Patients receiving only one treatment did
not contribute to the analyses of treatment contrasts but
remained in the population for the calculation of treatment
means. The safety population included all patients who
received at least one dose of the study drug and was used in
the analysis of all safety variables. For both populations,
the patients were analysed according to the treatment they
received.
For the primary efficacy variable, standardised FEV1
AUC22e24h, treatment differences between each indacaterol
dose and placebo were tested using analysis of covariance
(ANCOVA), with patient, period, and treatment group
modelled as fixed effects and period baseline FEV1 as
a covariate. Adjustment for multiple comparisons was made
using a stepwise Dunnett test. ANCOVA models were also
used to analyse all the secondary efficacy variables. ANCOVA
models were also used to provide between-indacaterol-dose
comparisons and comparisons with salmeterol; however,
these analyses were regarded as exploratory, because the
study was not powered for comparisons between the active
treatment groups. The corrected QT (QTc) interval wasTable 1 Patient demographics and baseline characteristics (saf
Parameters
Age, years
Sex
Male
Female
Weight, kg
BMI, kg/m2
Duration of asthma, years
ICS daily dose fluticasone propionate equivalent, mg
FEV1 (pre-bronchodilator) at screening, L
% predicted FEV1 (pre-bronchodilator) at screening
FEV1 (post-bronchodilator) at screening, L
FEV1 reversibility*
Smoking history
Non-smokers
Ex-smokers
Smoking history, pack-years
ICS, inhaled corticosteroid; BMI, body mass index.
*% increase in FEV1 within 30 min after inhalation of salbutamol fromcalculated from the QT and RR intervals using Fridericia’s
formula (QTcF).24 All tests of hypotheses used were two-
tailed and interpreted at the 10% significance level (as this
was a dose-finding study). The data were analysed using SAS
statistical software version 8.1 (or higher) for Windows (SAS
Institute Inc., Cary, NC, USA).
Results
Patient disposition, demographics, and baseline
characteristics
Of 93 screened patients, 41 were randomised to treatment.
Out of the 41 randomised patients, 39 (95.1%) completed
the study. Two patients (4.9%) discontinued, one due to
unsatisfactory therapeutic effect after the second treat-
ment period (having received indacaterol 300 mg and
placebo) and the other withdrew consent after the first
treatment period (having received indacaterol 150 mg).
Table 1 shows the demographics and baseline characteris-
tics of the patients in the study, all of whom were
Japanese.
Efficacy
Indacaterol at all doses resulted in a statistically superior
(P < 0.001) adjusted mean standardised FEV1AUC22e24h
compared to placebo (Fig. 2), with treatmenteplacebo
differences of 180 (90% CI: 120, 250), 220 (150, 280), and
260 (190, 320) mL for the 150, 300, and 600 mg doses,
respectively, compared with a salmeteroleplacebo
difference of 170 (120, 220) mL. At all time points from
5 min to 24 h post-dose, all indacaterol doses showedety population).
Statistic Total (N Z 41)
Mean (SD) 47.8 (14.90)
Range 22e74
n (%) 20 (48.80)
n (%) 21 (51.20)
Mean (SD) 62.1 (11.50)
Mean (SD) 23.3 (3.39)
Mean (SD) 17.5 (14.60)
Range 0.1e49
Mean (SD) 351.2 (177.65)
Range 200e800
Mean (SD) 2.01 (0.66)
Mean (SD) 67.3 (9.87)
Range 50.5e84.2
Mean (SD) 2.4 (0.79)
Mean (SD) 20.1 (7.90)
n (%) 29 (70.7)
n (%) 12 (29.3)
Mean (SD) 4.3 (2.83)
FEV1 before inhalation of salbutamol.
Figure 2 Primary endpoint: standardised FEV1AUC22-24h LS mean (SE) (mITT population). AUC, area under curve; SE, standard
error; LS, least squares; mITT, modified intent-to-treat. *P < 0.001 vs placebo; yP < 0.05 vs indacaterol 150 mg; zP < 0.05 vs
salmeterol 50 mg bid.
Figure 3 LS mean FEV1 (a) over 24 h and (b) 0e4 h post-dose
(mITT population). LS, least squares; mITT, modified intent-to-
treat. ( ) placebo, ( ) salmeterol 50 mg bid, ( )
indacaterol 150 mg, ( ) indacaterol 300 mg and ( )
indacaterol 600 mg. All indacaterol doses superior to placebo
(p < 0.001) at all post-dose time points and superior to
salmeterol (p < 0.05) from 5 to 30 min post-dose.
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adjusted mean FEV1 as compared with placebo (Fig. 3). In
addition, all doses of indacaterol were statistically supe-
rior (P < 0.05) to salmeterol from 5 min to 30 min post-
dose.
Indacaterol resulted in a significantly greater peak FEV1
compared with placebo (P < 0.001) and numerically (150
and 300 mg) or statistically (600 mg) higher peak FEV1
compared with salmeterol 50 mg bid. All indacaterol doses
resulted in significantly higher (P < 0.001) adjusted mean
FEV1AUC0e24h than placebo with treatmenteplacebo
differences of 220 (90% CI: 170, 270) mL, 270 (220, 320) mL,
and 310 (260, 360) mL for the 150, 300, and 600 mg doses,
respectively, and a salmeteroleplacebo difference of 200
(150, 240) mL. When compared with salmeterol, the
standardised FEV1AUC0e24h was significantly greater with
indacaterol 600 mg (110 mL; P < 0.001) and 300 mg (80 mL;
PZ 0.0096), and numerically higher with indacaterol
150 mg (30 mL; PZ 0.34). All indacaterol doses showed
significantly higher FVC, FEF25e75%, and percent change
from period baseline in FEV1 than placebo at all post-dose
time points (P < 0.002), with profiles similar to those
observed for FEV1 (data not shown). Indacaterol also
showed higher FVC, FEF25e75%, and percent change from
period baseline in FEV1 than salmeterol at the majority of
the post-dose time points.
Safety
Indacaterol doses were well tolerated, with no deaths or
SAEs reported. The overall incidence of AEs during the
double-blind treatment phase was 27.5% (11/40), 45.0%
(18/40), 40.0% (16/40), and 56.4% (22/39) for placebo and
indacaterol 150, 300, and 600 mg, respectively (Table 2).
The most commonly reported AE with indacaterol treat-
ment was cough, which was mostly mild in severity and
transient in nature, occurring just after inhalation of the
study drug.There were no minimum post-baseline potassium values
(below 3.0 mmol/L) with any of the treatments, maximum
post-baseline glucose values (above 9.99 mmol/L) were
Table 2 Number of patients (%) with AEs and by primary SOC (safety population).
AEs Indacaterol Salmeterol Placebo
150 mg
N Z 40
300 mg
N Z 40
600 mg
N Z 39
50 mg bid
N Z 39
N Z 40
n (%)
Total number of patients with AEs 18 (45.0) 16 (40.0) 22 (56.4) 2 (5.1) 11 (27.5)
Primary SOC affected
Respiratory, thoracic, and mediastinal disorders 14 (35.0) 13 (32.5) 15 (38.5) 0 5 (12.5)
Nervous system disorders 2 (5.0) 3 (7.5) 1 (2.6) 1 (2.6) 3 (7.5)
Gastrointestinal disorders 2 (5.0) 1 (2.5) 0 1 (2.6) 0
Infections and infestations 2 (5.0) 0 2 (5.1) 0 1 (2.5)
Investigations 2 (5.0) 0 1 (2.6) 0 1 (2.5)
Musculoskeletal and connective tissue disorders 2 (5.0) 0 1 (2.6) 1 (2.6) 1 (2.5)
Ear and labyrinth disorders 0 1 (2.5) 1 (2.6) 0 1 (2.5)
Hepatobiliary disorders 1 (2.5) 0 0 0 0
Immune system disorders 0 0 1 (2.6) 0 0
Injury, poisoning, and procedural complications 0 0 1 (2.6) 0 0
Psychiatric disorders 1 (2.5) 0 0 0 0
Skin and subcutaneous tissue disorders 0 1 (2.5) 1 (2.6) 0 1 (2.5)
AEs, adverse events; SOC, system organ class.
A patient with multiple AEs on one treatment and under one SOC is counted only once for that organ class and the treatment regardless
of the number of AEs.
Table 3 Overall incidence of hypokalaemia, hyperglycaemia, abnormal values of pulse rate and blood pressure, and change
from baseline in QTc interval (Fridericia’s formula) (safety population).
Indacaterol Placebo
150 mg
N Z 40
300 mg
N Z 40
600 mg
N Z 39
N Z 40
n (%)
Serum potassium: minimum post-baseline valuea
Below lower limit of normal range 1 (2.5) 4 (10.0) 3 (7.7) 2 (5.0)
Below 3.0 mmol/L 0 0 0 0
Blood glucose: maximum post-baseline valuea
Above upper limit of normal range 22 (55.0) 21 (52.5) 26 (66.7) 20 (50.0)
Above 9.99 mmol/L 0 3 (7.5) 1 (2.6) 0
Pulse rate e maximum post-baseline valueb
Above 90 bpm 0 2 (5.0) 0 1 (2.5)
Systolic blood pressure e maximum post-baseline valuec
Above 140 mm Hg 7 (17.5) 6 (15.0) 5 (12.8) 5 (12.5)
Diastolic blood pressure e minimum post-baseline valuec
Above 90 mm Hg 6 (15.0) 6 (15.0) 4 (10.3) 7 (17.5)
QTc value e (Fridericia’s formula)d
Absolute values
>450 ms (males) 0 0 0 0
>470 ms (females) 0 0 0 0
Change from baseline
>60 ms 0 0 0 0
a The measurement of serum potassium and blood glucose levels were taken at pre-dose, and 15 min, 1 h, 4 h and 24 h post-dose for
each treatment.
b The measurement of pulse rate was taken at pre-dose, and at 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, 12 h, 22 h, 23 h, and 24 h post-dose for
each treatment.
c The measurement of blood pressure was taken at pre-dose, and 15 min, 1 h, 4 h, 12 h and 24 h post-dose for each treatment.
d ECG was taken at pre-dose, 1 h, 4 h, and 24 h post-dose for each treatment.
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Efficacy of indacaterol in asthma 1635reported with three patients following indacaterol 300 mg
and one patient following 600 mg, none of which were,
however, associated with AEs (Table 3).
As summarised in Table 3, the incidence of abnormal
values for pulse rate (>90 bpm) and diastolic (>90 mm Hg)
and systolic (>140 mm Hg) blood pressure was similar
between placebo and the indacaterol treatments, indicating
no relationship with indacaterol dose. No clinically signifi-
cant ECG abnormalities and no abnormal QTcF prolongation
(male: QTcF >450 ms; female: >470 ms) or change in QTcF
from baseline (>60 ms) were observed with any of the
treatments (Table 4).
Discussion
This was the first study to evaluate the 24-h bronchodilator
efficacy of single doses of indacaterol 150, 300, and 600 mg
in Japanese patients with asthma. This crossover study
showed that indacaterol provided sustained 24-h broncho-
dilation, with a fast onset of action and a good overall
safety and tolerability profile. A crossover design was
preferred because variations in FEV1 within patients were
expected to be less compared with variations in FEV1
between patients.
In the present study, the primary efficacy analysis
showed that all indacaterol doses were associated with
statistically significantly greater (P < 0.001) standardised
FEV1AUC22e24h than placeboda finding consistent with
a previous dose-ranging study.19 Furthermore, the corre-
sponding 90% CIs of the differences between the indaca-
terol doses and placebo were relatively narrow, indicating
the precision of the estimated differences. In terms of
comparisons between indacaterol doses, the 600 mg dose
was statistically superior to the 150 mg dose for this
endpoint, whereas there was no statistically significant
difference between indacaterol 150 and 300 mg. In previous
studies in patients with asthma in which indacaterol was
administered at a dose of 50e600 mg, there were similar
separations in efficacy between the lowest and highest
indacaterol dose.19e21,23,25 The current study would
suggest that, given the similar efficacy to salmeterol,
150 mg could be the minimal effective dose of indacaterol
in asthmae this would, however, need confirming in a more
comprehensive dose-finding study. The results of the
primary analysis of this study was supported by those of the
secondary efficacy analyses, demonstrating that all three
indacaterol doses had statistically significant higher peak
FEV1 and standardised FEV1AUC0e24h compared with
placebo (P < 0.001). In addition, all indacaterol doses
showed notable improvements in FEV1 at nearly all time
points over 24 h compared with placeboda finding also
consistent with earlier studies conducted mostly on the
Caucasian population.18e21,25 These results, together with
the 24-h profiles of FVC and FEF25e75%, indicate that inda-
caterol provided effective and sustained 24-h bronchodi-
lation, which further supports the potential for
a once-daily dosing regimen. Given the similar efficacy
demonstrated by indacaterol in Japanese and Caucasian
patients, this is an indication that indacaterol is likely to be
effective in the management of asthma regardless of
a patient’s ethnicity. This is an important consideration for
any bronchodilator, given there is an evidence ofdivergence in beta-2 adrenoceptor polymorphism haplo-
type frequency in the ethnic groups26 In addition, several
studies have investigated the polymorphisms of beta-2
adrenoceptor with regard to the bronchodilator response
to inhaled beta-2 agonists.27,28 However, in clinical studies
investigating the use of LABAs in COPD patients, there are
several reports that demonstrate similar response in
Japanese and Caucasian populations.29,30
In previous studies in the Caucasian population, inda-
caterol has shown a fast onset of action, similar to that of
salbutamol (a short-acting beta-2 agonist) and faster than
salmeterol.18 The results of our study are also consistent
with these findings, as significant improvements in FEV1
appeared as early as 5 min post-indacaterol dose (the
earliest time point evaluated), with all indacaterol doses
showing statistical superiority (P < 0.05) to salmeterol until
at least 30 min post-dose.
The convenience of once-daily dosing together with
sustained bronchodilation and a fast onset of action could
potentially enable enhanced patient compliance and
asthma control compared with twice-daily therapies.20
Thus indacaterol, when combined with a once-daily ICS,
could have an advantage in terms of patient acceptability,
convenience, and adherence to therapy. These aspects of
indacaterol treatment could not be assessed in the current
study, given the single-day dosing study design. Further-
more, salmeterol was administered on an open-label basis
in the final treatment period for all patients. This was for
practical purposes, and made the study design less complex
(with only one type of placebo inhaler required), and it
should be noted that the primary comparison was between
indacaterol and placebo. However, the inclusion of a LABA
active comparator is helpful in the interpretation of the
study results.
All indacaterol doses in the present study were well
tolerated and showed a good overall safety profile. No
patient treated with indacaterol discontinued the study
due to AEs. Most AEs reported in this study were expected
in this patient population and were similar to those
observed in previous studies conducted outside
Japan.17,18,20,31 The incidence of AEs reported in this study
was higher with indacaterol treatment than with open-
label salmeterol (which was taken by all patients during
the final treatment period). This difference in the rate of
AEs was due to the higher incidence of cough in patients
treated with indacaterol. The majority of cough AEs were
mild in severity, occurred just after inhalation of study
drug and were transient in nature. Notably, recording of
AEs was the only safety assessment performed for
salmeterol.
No deaths or SAEs were reported in this study. Given the
class effects of beta-2 agonists on serum potassium and
blood glucose, these parameters were analysed exten-
sively, and there was no clear relationship between the
incidence of hypokalaemia or hyperglycaemia and the
indacaterol doses. Furthermore, no major effect on the QT
interval and pulse rate was observed with the indacaterol
doses.
The overall safety and tolerability profile of indacaterol
was consistent with the previous studies that involved
repeated indacaterol doses for up to 28 days.17,27 Further
studies investigating the long-term efficacy and safety of
1636 N. Sugihara et al.indacaterol in a fixed-dose combination with an ICS are
planned.
In conclusion, single doses of indacaterol 150, 300, and
600 mg in combination with an ICS provided superior bron-
chodilation for 24-h with a faster onset of action compared
with salmeterol 50 mg bid in combination with an ICS in
Japanese patients with asthma. In addition, indacaterol
demonstrated a good overall safety and tolerability profile
in this patient population. Therefore, the development of
indacaterol in conjunction with an ICS could be a useful
treatment option for Japanese patients with asthma.
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